tirzepatide cardiovascular outcome trial outcomes Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of Effects of Tirzepatide on the

The obese and overweight group demonstrated a higher risk for NAION than the T2D group ( HR = 7.64 )

2025 GLP-1 research shows that GLP-1 agonists like semaglutide and tirzepatide not only help reduce weight but may also play an indirect role in improving cardiometabolic outcomes, such as blood pressure and lipid profiles

The Wegovy Results Timeline: Month by Month Note: This timeline is based on published STEP trial data and represents averages

Fats stay adequate, around 30 to 50 g a day at minimum, partly for hormones and partly because very low fat intake during rapid changes raises gallbladder risk in the broader literature

Depression thats causing inflammation , especially if your hs-CRP or other inflammatory markers are elevated